Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Application of Artificial Intelligence in Chronic Myeloid Leukemia (Cml) Disease Prediction and Management: A Scoping Review Publisher Pubmed



Ram M1 ; Afrash MR2 ; Moulaei K3 ; Parvin M4 ; Esmaeeli E5 ; Karbasi Z6 ; Heydari S5 ; Sabahi A7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Faculty of Medical Sciences, Birjand university of medical sciences, Birjand, Iran
  2. 2. Department of Artificial intelligence, Smart University of Medical Sciences, Tehran, Iran
  3. 3. Department of Health Information Technology, School of Paramedical, Ilam University of Medical Sciences, Ilam, Iran
  4. 4. Department of Industrial and Systems Engineering, Auburn University, Auburn, AL, United States
  5. 5. Department of Health Information Management and Medical Informatics, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Health Information Sciences, Faculty of Management and Medical Information Sciences, Kerman University of Medical Sciences, Kerman, Iran
  7. 7. Department of Health Information Technology, Ferdows faculty of Medical Sciences, Birjand University of Medical Sciences, Birjand, Iran

Source: BMC Cancer Published:2024


Abstract

Background: Navigating the complexity of chronic myeloid leukemia (CML) diagnosis and management poses significant challenges, including the need for accurate prediction of disease progression and response to treatment. Artificial intelligence (AI) presents a transformative approach that enables the development of sophisticated predictive models and personalized treatment strategies that enhance early detection and improve therapeutic interventions for better patient outcomes. Methods: An extensive search was conducted to retrieve relevant articles from PubMed, Scopus, and Web of Science databases up to April 24, 2023. Data were collected using a standardized extraction form, and the results are presented in tables and graphs, showing frequencies and percentages. The authors adhered to the PRISMA-ScR checklist to ensure transparent reporting of the study. Results: Of the 176 articles initially identified, 12 were selected for our study after removing duplicates and applying the inclusion and exclusion criteria. AI’s primary applications of AI in managing CML included tumor diagnosis/classification (n = 9, 75%), prediction/prognosis (n = 2, 17%), and treatment (n = 1, 8%). For tumor diagnosis, AI is categorized into blood smear image-based (n = 5), clinical parameter-based (n = 2), and gene profiling-based (n = 2) approaches. The most commonly employed AI models include Support Vector Machine (SVM) (n = 5), eXtreme Gradient Boosting (XGBoost) (n = 4), and various neural network methods, such as Artificial Neural Network (ANN) (n = 3). Furthermore, Hybrid Convolutional Neural Network with Interactive Autodidactic School (HCNN-IAS) achieved 100% accuracy and sensitivity in organizing leukemia data types, whereas MayGAN attained 99.8% accuracy and high performance in diagnosing CML from blood smear images. Conclusions: AI offers groundbreaking insights and tools for enhancing prediction, prognosis, and personalized treatment in chronic myeloid leukemia. Integrated AI systems empower healthcare practitioners with advanced analytics, optimizing patient care and improving clinical outcomes in CML management. © The Author(s) 2024.